Literature DB >> 20890118

Cross-talk between post-translational modifications regulate life or death decisions by E2F1.

Haroula Kontaki, Iannis Talianidis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20890118     DOI： 10.4161/cc.9.19.13384

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  Deciphering a global network of functionally associated post-translational modifications.

Authors:  Pablo Minguez; Luca Parca; Francesca Diella; Daniel R Mende; Runjun Kumar; Manuela Helmer-Citterich; Anne-Claude Gavin; Vera van Noort; Peer Bork
Journal:  Mol Syst Biol       Date:  2012-07-17       Impact factor: 11.429

2.  Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells.

Authors:  María F Montenegro; María Del Mar Collado-González; María Piedad Fernández-Pérez; Manel B Hammouda; Lana Tolordava; Mariam Gamkrelidze; José Neptuno Rodríguez-López
Journal:  BMC Cancer       Date:  2014-07-26       Impact factor: 4.430

Review 3.  Targeting the epigenetic machinery of cancer cells.

Authors:  M F Montenegro; L Sánchez-del-Campo; M P Fernández-Pérez; M Sáez-Ayala; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

4.  Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation.

Authors:  María F Montenegro; Magali Sáez-Ayala; Antonio Piñero-Madrona; Juan Cabezas-Herrera; José Neptuno Rodríguez-López
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

5.  SET9-Mediated Regulation of TGF-β Signaling Links Protein Methylation to Pulmonary Fibrosis.

Authors:  Maximilianos Elkouris; Haroula Kontaki; Athanasios Stavropoulos; Anastasia Antonoglou; Kostas C Nikolaou; Martina Samiotaki; Eszter Szantai; Dimitra Saviolaki; Peter J Brown; Paschalis Sideras; George Panayotou; Iannis Talianidis
Journal:  Cell Rep       Date:  2016-06-09       Impact factor: 9.423

6.  The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.

Authors:  Raffaella Soldi; Tithi Ghosh Halder; Alexis Weston; Trason Thode; Kevin Drenner; Rhonda Lewis; Mohan R Kaadige; Shreyesi Srivastava; Sherin Daniel Ampanattu; Ryan Rodriguez Del Villar; Jessica Lang; Hariprasad Vankayalapati; Bernard Weissman; Jeffrey M Trent; William P D Hendricks; Sunil Sharma
Journal:  PLoS One       Date:  2020-07-10       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.